Marvel Biosciences EBIT

The latest EBIT for MRVL.V is $-1.9M as of April 2026. That compares with $-1.5M in the prior-year period — down 30.2% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Marvel Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, MRVL.V's EBIT moved from $-1.5M to $-1.9M — a 30.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Marvel Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, MRVL.V currently prints $-1.9M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Marvel Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-1.9M for MRVL.V is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting MRVL.V's EBIT ($-1.9M), review year-over-year change from $-1.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.